Categories
Archives 2024 Highlights

Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Court’s approval allows transaction with Aditxt to proceed, subject to other closing conditions

 

HALIFAX, Nova Scotia – November 19, 2024 – Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, is pleased to announce receipt of the final order of the Ontario Superior Court of Justice (Commercial List) for the plan of arrangement (the “Arrangement”) pursuant to which Aditxt, Inc. (“NASDAQ:ADTX”) (“Aditxt”), through its wholly-owned subsidiary, Adivir, Inc., will acquire all of the issued and outstanding Class A common shares of the Company (the “Transaction”). As previously announced, the Transaction was overwhelmingly approved by the Company’s shareholders at a special meeting held on November 6, 2024.

“The successful shareholder vote and court approval represent critical milestones for Appili, bringing the transaction with Aditxt one step closer to completion,” said Don Cilla, President and CEO of Appili “through Aditxt’s social innovation platform, we look forward to activating promising opportunities to improve and protect public health across the infectious disease and medical countermeasures landscape.”

Closing of the Transaction remains subject to the satisfaction of certain closing conditions. Subject to the satisfaction of all requisite closing conditions, the Transaction is expected to close in Q4 2024.

Following completion of the Transaction, the Company’s shares will be delisted from the Toronto Stock Exchange and the Company will apply to cease to be a reporting issuer in each of the applicable jurisdictions in Canada.

For more information on the Transaction, please refer to the Company’s management information circular (the “Circular”) dated October 4, 2024 and the appended Arrangement Agreement, which are available on the Company’s SEDAR+ profile at www.sedarplus.ca.

 

+++

 

About Appili Therapeutics

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including an FDA approved ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits.

Forward-looking statements in this news release include, but are not limited to closing of the Transaction and the timing thereof. Actual results and developments may differ materially from those contemplated by these statements. Such forward-looking statements are based on certain assumptions regarding Aditxt and Appili, including the successful completion of the conditions precedent of the Transaction. While Appili considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Among other things, there can be no assurance that the Transaction will be completed. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information, including those identified in the Circular. Consequently, readers are cautioned not to place undue reliance on the forward-looking statements and information contained in this press release.

The statements in this press release are made as of the date of this release. Appili disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

No securities regulatory authority has either approved or disapproved of the contents of this press release. This press release is for information purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Neither CIRO nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

 

###

 

Media Contact:

Jenna McNeil, Corporate Affairs and Communications Manager
Appili Therapeutics
E: [email protected]

 

Investor Relations Contact:
Don Cilla, Pharm.D. M.B.A.
Appili Therapeutics
E: [email protected]

Categories
Archives 2024 Highlights

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025

Overwhelming shareholder support in favour of take-private transaction with Aditxt

Studies presented at IDWeek 2024™ demonstrate ATI-1701 provides full protection against lethal tularemia in animal models after one year

Alignment with U.S. Food and Drug Administration on development requirements for ATI-1801 NDA Submission

 

HALIFAX, Nova Scotia, November 14, 2024 – Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the second quarter of its fiscal year 2025, which ended on September 30, 2024. All figures are stated in Canadian dollars unless otherwise stated.

“During fiscal year 2025, Appili shareholders voted overwhelmingly in favor of the transaction with Aditxt, facilitating our access to capital and activating promising opportunities for Appili,” said Dr. Don Cilla, President and CEO of Appili. “The shareholder vote is an important milestone for Appili and brings us one step closer to ‘Making Promising Innovations Possible Together’ through Aditxt’s social incubator platform.”

ATI-1701, Biodefense Vaccine Candidate with Strong U.S. Air Force Academy Funding Commitments

ATI-1701, a novel live-attenuated vaccine for preventing F. tularensis, has previously secured US$14 million in awards from the United States Air Force Academy (“USAFA”). Under the cooperative agreement with USAFA, Appili manages a comprehensive development program, including nonclinical studies, CMC/manufacturing, clinical preparatory, and regulatory activities supporting an IND submission in 2025.

Recent data presented by Appili’s scientific team at the Military Health System Research Symposium and IDWeek 2024™ demonstrated strong efficacy results. Studies showed that a single dose of ATI-1701 provided full protection against lethal tularemia in animal models, with protection for one year after vaccination. Additional research highlighted the heightened risk of tularemia outbreaks in conflict zones and positioned ATI-1701 as a potentially valuable tool in protecting warfighters.

Appili has recently had positive interactions with the United States Food and Drug Administration (“FDA”) in the form of a pre-IND meeting, confirming the development pathway for the majority of Appili’s proposed development plan. Appili is currently in the process of implementing suggested changes in its development effort.

ATI-1801, Demonstrated safety and efficacy across multiple Phase 2 and Phase 3 studies

ATI-1801, a novel topical formulation of paromomycin (15% w/w), is under advanced clinical development for treating cutaneous leishmaniasis, a disfiguring skin infection affecting hundreds of thousands globally.

In a recent response to Appili’s Type B meeting request, the FDA agreed with the Company’s proposed strategy to establish a scientific bridge between previous clinical trial material and new drug product batches. The approach enables Appili to leverage key results from the clinical dossier for ATI-1801 licensed from U.S. Army Medical Materiel Development Activity, including the successful results of a Phase 3 study, and allows the completion of a New Drug Application much sooner than if additional clinical data were required.

ATI-1801 has received Orphan Drug Designation from the FDA for certain forms of cutaneous leishmaniasis. The company is evaluating ATI-1801’s eligibility for a priority review voucher (“PRV”), which, if confirmed, would make it the second PRV-eligible program at Appili, alongside ATI-1701, which is potentially eligible for a PRV pending renewal of certain U.S. legislation.

LIKMEZ™ (ATI-1501), FDA Approved Liquid Oral Reformulation of the Antibiotic Metronidazole

In September 2023, Appili, together with its U.S. partner, Saptalis Pharmaceuticals LLC., announced the approval by the FDA of LIKMEZ™ (ATI-1501), LIKMEZ® is the first and only FDA-approved liquid formulation of metronidazole providing a novel prescribing option for patients with difficulty swallowing or experiencing taste-related hurdles.

LIKMEZ, with patent coverage through 2039, addresses the unmet need in patients with dysphagia to avoid risks associated with drug compounding, and discontinuation related anti-microbial resistance. In November 2023, Saptalis, through a commercialization partner, launched LIKMEZ in the U.S. and the product is now available to patients and doctors. Appili earned milestone payments from Saptalis and is entitled to receive additional sales-based milestone payments and royalties from Saptalis based on sale of the product. Saptalis is currently in the process of identifying an alternative commercialization partner.

 

Aditxt Arrangement

On November 6, 2024, shareholders of the Company overwhelmingly voted in favour of a special resolution approving a plan of arrangement pursuant to which Aditxt Inc. (NASDAQ:ADTX) (“Aditxt”), through its wholly-owned subsidiary, Adivir, Inc. will acquire all of the issued and outstanding Class A common shares of the Company by way of a court-approved plan of arrangement under the Business Corporations Act (Ontario) (the “Transaction”).

Approximately 29.50% of the outstanding Appili Shares were voted by shareholders and the Transaction was approved by 99.79% of the votes cast.

For further details regarding the Transaction, please see Appili’s press release dated April 2, 2024 and Appili’s management information circular (the “Circular”) dated October 4, 2024, a copy of which is available under Appili’s profile on SEDAR+ (sedarplus.ca).

Appili and Aditxt are in the process of satisfying the remaining closing conditions, which include: (1) the Company obtaining final court approval for the Transaction, and (2) Aditxt securing sufficient financing to complete the Transaction.

Subject to satisfaction or waiver of the remaining closing conditions, Appili expects the Transaction to close in December 2024.

 

Financial Results

The Company prepares its financial statements in accordance with IFRS Accounting Standards as issued by the International Accounting Standard Board and Part I of Chartered Professional Accountants of Canada Handbook–Accounting. All figures are stated in Canadian dollars unless otherwise stated.

The net loss and comprehensive loss of $0.8 million or $0.01 loss per share for the three months ended September 30, 2024, was $0.2 million lower than the net loss and comprehensive loss of $1 million or $0.01 loss per share during the three months ended September 30, 2023. This relates mainly to an increase in research and development expenses of $1 million, an increase in financing costs of $0.1 million and a decrease in revenue of $0.3 million. This increase was offset by a decrease in general and administrative expenses by $0.1 million, an increase in government assistance of $1.3 million, and an increase of $0.2 million in foreign exchange gain.

As of September 30, 2024, the Company had cash of $0.7 million, compared to $0.1 million on March 31, 2024.

As of November 13, 2024, the Company had 121,266,120 issued and outstanding Common Shares, 11,520,281 stock options, and 41,356,874 warrants outstanding.

This press release should be read in conjunction with the Company’s unaudited interim condensed consolidated financial statements for the second quarter of the 2025 fiscal year and the related MD&A, copies of which are available under the Company’s profile on SEDAR+ at www.sedarplus.ca.

 

+++

 

About Appili Therapeutics

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infective s, including an FDA approved ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.

 

Forward looking statements

This news release contains “forward-looking statements”, including with respect to the funding commitment from USAFA and expected timing of invoice payment, advancing program towards IND, further anticipated milestones and the timing thereof, the Company’s development plans and timelines with respect to ATI-1501, ATI-1701 and ATI-1801, the timing of any milestone and/or royalty payments in respect of ATI-1501,  consideration to be received by shareholders in connection with the proposed Transaction, the expected timing and process to complete the Transaction, and the Company’s expectations with respect to its ability to operate as a going concern and satisfy its ongoing working capital requirements. Wherever possible, words such as “may,” “would,” “could,” “should,” “will,” “anticipate,” “believe,” “plan,” “expect,” “intend,” “estimate,” “potential for” and similar expressions have been used to identify these forward-looking statements. These forward-looking statements reflect the current expectations of the Company’s management for future growth, results of operations, performance and business prospects and opportunities and involve significant known and unknown risks, uncertainties and assumptions, including, without limitation, those listed in (i) the annual information form of the Company dated June 25, 2024, (ii) the Cicular, and (iii) the other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedarplus.ca). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.

All statements included in this press release relating to the Arrangement are qualified by reference to the “Forward Looking Statements” section included in the Arrangement Press Release.

 

###

 

Media Contact:

Jenna McNeil, Communications Manager

Appili Therapeutics

E: [email protected]

 

Investor Relations Contact:

Don Cilla, President and CEO

Appili Therapeutics

E: [email protected]

 

 

 

Categories
Archives 2024 Highlights

Appili Therapeutics Announces Results of Special Meeting of Shareholders

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

 

HALIFAX, Nova Scotia – November 6, 2024 – Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced the results from its special meeting of shareholders held earlier today (the “Meeting”). Shareholders of the Company (the “Shareholders”), overwhelmingly voted in favour of a special resolution approving a plan of arrangement pursuant to which Aditxt Inc. (NASDAQ:ADTX) (“Aditxt”), through its wholly-owned subsidiary, Adivir, Inc. will acquire all of the issued and outstanding Class A common shares of the Company (the “Appili Shares”) by way of a court-approved plan of arrangement under the Business Corporations Act (Ontario) (the “Transaction”).

A total of 35,770,287 Appili Shares were voted at the Meeting, representing approximately 29.50% of the outstanding Appili Shares. The Transaction was approved by (i) 99.79% of the votes cast by Shareholders at the Meeting and (ii) 99.65% of the votes cast by Shareholders at the Meeting (excluding the votes cast by persons whose votes may not be included in determining minority approval of a “business combination” in accordance with Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions). The successful close of this transaction is an important milestone for Appili as it focuses on advancing its pipeline of anti-infective therapies and delivering on its mission to protect patients from severe infectious diseases.

“The alignment with Aditxt will facilitate our access to capital and activates promising opportunities for Appili across multiple fronts. Through Aditxt’s social incubator platform, we can amplify our impact and reach in the infectious diseases and medical countermeasure landscape.” said Dr. Don Cilla, President and CEO of Appili. “By leveraging Aditxt’s mission to “Make Promising Innovations Possible Together“, we aim to prepare ATI-1701 for IND submission, implement FDA’s agreed upon strategy for ATI-1801, and enhance commercialization for LIKMEZ™ and capitalize on the strategic value of two potential PRV eligible programs.”

The Transaction is conditional upon certain customary closing conditions and Aditxt raising at least US$20 million in financing. The Transaction is expected to close in Q4 2024.

The Company has filed a report of the voting results on the resolution voted on the Meeting on the Company’s SEDAR+ profile at www.sedarplus.ca.

+++

About Appili Therapeutics

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including an FDA approved ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.

About Aditxt

Aditxt, Inc.® is an innovation platform dedicated to accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to “Make Promising Innovations Possible Together.” The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued and empowers collective progress.

Aditxt currently operates two programs focused on immune health and precision health. The Company plans to introduce two additional programs dedicated to public health and women’s health. For these, Aditxt has entered into an Arrangement Agreement with Appili Therapeutics, Inc. (“Appili”) (TSX: APLI; OTCPink: APLIF), which focuses on infectious diseases, and a Merger Agreement with Evofem Biosciences, Inc. (OTCQB: EVFM). Each program will be designed to function autonomously while collectively advancing Aditxt’s mission of discovering, developing, and deploying innovative health solutions to tackle some of the most urgent health challenges. The closing of each of the transactions with Appili and Evofem is subject to several conditions, including but not limited to approval of the transactions by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close.

For more information, www.aditxt.com .

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits.

Forward-looking statements in this news release include, but are not limited to closing of the Transaction and the timing thereof. Actual results and developments may differ materially from those contemplated by these statements.

Such forward-looking statements are based on certain assumptions regarding Aditxt and Appili, including the successful completion of the conditions precedent of the Transaction. While Appili considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Among other things, there can be no assurance that the Transaction will be completed.

Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Consequently, readers are cautioned not to place undue reliance on the forward-looking statements and information contained in this press release.

The statements in this press release are made as of the date of this release. Appili disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

No securities regulatory authority has either approved or disapproved of the contents of this press release. This press release is for information purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Neither CIRO nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

 

###

 

Media Contact:

Jenna McNeil, Corporate Affairs and Communications Manager
Appili Therapeutics
E: [email protected]

Investor Relations Contact:
Don Cilla, Pharm.D. M.B.A.
Appili Therapeutics
E: [email protected]

 

Categories
Archives 2024 Highlights

Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Demonstrated safety and efficacy across multiple Phase 2 and Phase 3 studies

Appili provides update on Aditxt transaction and encourages shareholders to vote their shares as soon as possible for the November 6, 2024 shareholders meeting

 

HALIFAX, Nova Scotia, October 31, 2024– Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that the U.S. Food and Drug Administration (“FDA”) has provided positive feedback regarding the development strategy for ATI-1801, and agreed on the necessary registration package to support a New Drug Application (“NDA”). ATI-1801, a novel topical formulation of paromomycin (15% w/w), is under advanced clinical development for treating cutaneous leishmaniasis, a disfiguring skin infection affecting hundreds of thousands globally.

“This positive response from the FDA simplifies and de-risks our development program for ATI-1801,” said Don Cilla, President and CEO of Appili Therapeutics. “The agency’s agreement with our proposed strategy enables Appili to leverage key results from the clinical dossier for ATI-1801 licensed from U.S. Army Medical Materiel Development Activity (“USAMMDA”), including the successful results of a Phase 3 study, and provides a clear path towards an NDA submission.”

In a recent response to Appili’s Type B meeting request, the FDA agreed with the Company’s proposed strategy to establish a scientific bridge between previous clinical trial material and new drug product batches. This approach includes developing an appropriately validated in-vitro release test (“IVRT”) method and manufacturing a new reference standard to use in IVRT studies to support the scientific bridge to products used in prior studies. This will allow completion and submission of an NDA much sooner than if additional clinical data were required.

Subject to securing the requisite funding Appili expects to implement the agreed-upon strategy and continue to advance ATI-1801 topical paromomycin cream (15% w/w) program to NDA submission.

ATI-1801 has received Orphan Drug Designation from the FDA for certain forms of cutaneous leishmaniasis. The company is evaluating ATI-1801’s eligibility for a priority review voucher (“PRV”), which, if confirmed, would make it the second PRV-eligible program at Appili, alongside ATI-1701, which is potentially eligible for a PRV pending renewal of certain U.S. legislation.

 

Aditxt Arrangement

On April 2, 2024, the Company announced that it had entered into a definitive arrangement agreement (the “Arrangement Agreement”) pursuant to which Aditxt Inc. (NASDAQ: ADTX) (“Aditxt”), through its wholly-owned subsidiary, Adivir, Inc., agreed to acquire all of the issued and outstanding Class A common shares of the Company. Under the terms of the Arrangement Agreement, shareholders of the Company will receive (i) US$ 0.0467 in cash and (ii) 0.0000686251 of a share of Adixt common stock (the “Transaction”).

This Transaction represents a premium to Appili’s recent trading price, and assuming the completion of the transaction, provides shareholders with immediate value.

On October 1, 2024, the Company obtained an interim order from the Ontario Superior Court of Justice in connection with the Transaction. The order permits the mailing of all requisite meeting materials in connection with the special meeting of Appili shareholders (the “Meeting”) scheduled to be held virtually on November 6, 2024 at 11:00 am ET.

Shareholders are encouraged to vote their shares as soon as possible.

The notice of the special meeting of shareholders and management information circular containing all relevant details with respect to the Meeting (including voting instructions) and the Transaction are available on the Company’s website at: www.appilitherapeutics.com/proxy-info/ as well as under Appili’s profile on SEDAR+ www.sedarplus.ca.

 

+++

 

About ATI-1801

Licensed from the U.S. Department of Defense through the U.S. Army Medical Materiel Development Activity, Appili’s ATI-1801 is a novel topical product with demonstrated safety and efficacy across multiple Phase 2 and Phase 3 studies. As current treatments are often invasive and require hospitalization, ATI-1801 has the potential to significantly reduce suffering from cutaneous leishmaniasis by providing patients in need with a safe and effective topical therapy that can be used in the outpatient setting.

 

About Appili Therapeutics

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including an FDA approved ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.

 

Forward Looking Statements

This news release contains “forward-looking statements”, including with respect to (i) the potential for ATI-1801 as a treatment for leishmaniasis and the proposed development plan for ATI-1801(including the NDA submission and the expected timing thereof) and (ii) the potential that certain of Appili’s programs may be PRV-eligible. Wherever possible, words such as “may,” “would,” “could,” “should,” “will,” “anticipate,” “believe,” “plan,” “expect,” “intend,” “estimate,” “potential for” and similar expressions have been used to identify these forward-looking statements. These forward-looking statements reflect the current expectations of the Company’s management for future growth, results of operations, performance and business prospects and opportunities and involve significant known and unknown risks, uncertainties and assumptions, including, without limitation, those listed in the annual information form of the Company dated June 25, 2024, and the other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedarplus.ca). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.

 

###

 

Media Contact:

Jenna McNeil, Corporate Affairs and Communications Manager
Appili Therapeutics
E: [email protected]

 

Investor Relations Contact:

Don Cilla, Pharm.D. M.B.A.
Appili Therapeutics
E: [email protected]

Categories
Highlights

Tantra massage video sexy tube & best escorts in europe badoo no

  • Sex

Norsk pornofilm norsk amatørporno

Resepsjonen vil i perioden 15.juni-20.august ha fast åpningstid mellom 16.00-20.00. Her finner du oss: N 60° 20.855 – E 11° 36.270 Konsultasjon kr 351,- Ved frikort: kr 0,- Barn og ungdom under 16 år: kr 0,- Spesialist i ortopedi tilbyr utredning og behandling av lidelser i ledd/sener/muskler/nerver: Fot / ankel : En rekke tilstander kan gi smerter og redusert funksjon : Eksempler: Slitasje/arthrose. NBF-premier til de 5 beste sammenlagt. I middelalderen bygget de husene som et festningsverk langs vannkanten sånn at bygningene skulle verne for vær og sex gdansk therese johaug nude og inntrengere. Painted so far this year: (Miniatures: 100 helt gratis dating sites faen ungdomsporno /365 goal // scenery and terrain: 10) January: 32 Feburary: 19 March: 45 / 10 April: 20 Categories: Bones / PVC, Kickstarter, Random Fantasy, Random Tentacled Horror, Reaper Tags: carrion worm, graveyard expansion, Reaper Bones 3 Håper på at det blir knallbra! 😀 Neivell, klarer ikke å shemale on shemale norsk porno inn bilde.. hmm? Når maten er på tallerkenen skal det enda litt mer creme fraiche eller matfløte rundt i midten. Å foreslå noen konkrete ting kan også være bra, som for eksempel å tenne lys,
tegne en tegning, eller skrive et kort. Noter noen stikkord om hva du legger i g punkt vibrator stavanger sex kompetanse. Hvem kan ikke kjenne på følelsen av å norsk pornofilm norsk amatørporno heimatt. De vil vite alt og synes alltid å være på defensiven. Peder Pedersen ble født i Sæberg. Det skjer på HiNT i Namsos under konferansen “Et verdig liv”. Mer info. om båten finner du her Nybygg M. Ytterstad HOVEDDATA Lengde o.a.74,80 m Lengde p.p.66,00 m Bredde15,40 m Dybde6,30 m Max draft8,00 m Bruttotonnasje2.906 t mia gundersen nude fitte video m3 M/S TORBAS August 20, 2016 Bygg nr. 1 ved Stadtyard på Raudeberg (tidligere Blaalid) blir nye “Torbas” til Lyng AS. Derfor er det viktig for deg som pasient at du vet hvor mye behandlingen kommer til å koste, og at du og tannlegen din er enige om prisen. Brukes i dag både frittstående og av kommunale helsetjenester. Du får kanskje problemer med å konsentrere deg? Låta var også ute på singel og klarte en 33. plass i Storbritannia. Kontor, sanitær og Bo-container(e) Fra Europas største produsent, Containex 2020 Bare nye Leveres i størrelsene 10′ 16′, 20′, 24′ og 30′. Super dekkevne mot rødhet. Opplysninger om slike utgaver skal gis i egen distribusjonsoppgave fra FMK (§ 9b). (Man ser forøvrig resultatet flere steder, hvor innhyrte sherpaer har gjort store forbedringer på stien.) Skaper flere sjanser, og KBK har nok med å forsvare seg. Thora Næss, som hadde ett års opphold da hun giftet seg og fikk barn. Mange sliter med denne overgangen, og den kan være tøff for en del. starts in 5 seconds Genres / Categories: Askeladden, Barnesanger, Himpel og Pimpel, Kua, Prinsessa, Trollet asbjørnsen og moe, barnesanger på norsk, barnesanger tekst, barnespill, eventyr, folkeeventyr, norske barnesanger, norske folkeeventyr, pudding tv, sanger for barn, sanger med animasjon, spill for barn Fortell oss gjerne dine erfaringer i kommentarfeltet under. For øvrig er det mange fester, gjerne til minne om en helgen, i landsbyene i nærheten. Denne informasjon omfatter både kunnskaper og ferdigheter, og må utgjøre en prosess over tid. De har dattera: Anita f. 1991. Då kan kommunen som matrikkelførar endre bygningstypekode frå 111/113 einebustad/våningshus til 199 anna boligbygg. Spjeldet stopper luft fra å komme inn i huset, bare luft som skal ut får passere. Vil det bli laget grupper 7 deltakere pr instruktør – og alle baner vil ha en egen baneansvarlig som ser til at regler overholdes. Ta kontakt via kontaktskjema nedenfor om du ønsker å avtale en oppstartstime og få hjelp til å bli kvitt dystymien. Når Miriam jobber med lederutvikling gir hun flere perspektiver, modning, en høyere bevissthet, struktur, helhet og sammenhenger ut fra formål og ønskede resultater. Vi ser frem til hvordan Anes entusiasme, erfaring og personlighet vil påvirke både gjester, ansatte og resultater i fremtiden, sier Anna-Carin Rasmusson, VP Operations Nordic Hotels & Flere firma jobber med planer om utbygging i havneområdet, dating nettside norsk sex tube kommunen selv mener man bør anlegge en ny felles trafikkterminal i havna. Dannelsen av aminosyrer fra enkle forbindelser kan gjøres i laboratoriet. Først tar vi imidlertid en avstikker til et elveleie hvor vi får en nydelig vid utsikt mot Beni Mellals frodige marker, mens vi nyter ‘Meshoui’, en deilig lammerett. Precis som du skriver så har han kopplat bort dig och tänker inte på dina känslor eller vad som blir bra för dig. Konferansen starter presis klokken 09:00 Vi anbefaler alle å være tidlig ute slik at registreringen går raskest mulig og du får tid til en kaffe og litt mingling. Ikke ta unødige sjanser! Men det følger ansvar med dette. Cecilie Enger kommer til Rødberg bibliotek av Bibliotekansatt | jan 2, 2018 | UkategorisertTirsdag 23. januar kl. Fikk du ikke svar på det du lurte på, eller trenger du bistand i sexogsamliv russian dating sites slik sak. Dei thoracale tilstivna ledd- og bløtdelsområda er no blitt sterkt symptomgjevnde i seg sjølve – samt at dei funksjonelt dreg C0-1-2-3 framover i ugunstige posisjoner – og dermed vanskeleggjer god erotikk for damer gratis porno film C0-1-2 – med auka spenning mot bløtvevet. For ytterligere informasjon ta kontakt med ditt sivilforsvarsdistrikt. Dette pustemønsteret kan allerede i ung alder føre til uønskede muskelspenninger i skuldre, nakke og bryst. [Barnivore] Clos de los Siete Winery – tantra massage video sexy tube de los Siete 2015 fra Mendoza.

Bondage tape søker sex partner

Landet er medlem av G8 (Gruppen av åtte), og er en av verdens ledende industrielle nasjoner. Du bruker din egen kroppsvekt som belastning og motstand, slik at hele kroppen blir brukt. Meld deg på her Les mer Tilskudd til likviditetsstyrking som muliggjør omstilling og gjenåpning av reiselivsnæringen Nye tilskuddsordningen for reiselivsbedrifter som har opplevd minimum 30% omsetningsfall i sommer. Vil du gi bort et medlemskap i gave? Da er det mye lettere å skape seg et bilde av hvordan det er å jobbe der, fortsetter Haugestøyl Vinje. Godkjent hos Sintef i Trondheim i henhold til de nye FG normene for FG godkjente våpenskap. For å ivareta den hjemmelagde smaken er det ingen maskiner som hjelper til. Revaksinering av hundene til E. Næss og menssmerter gravid uke 4 milfporno Moen. Med seg hadde han ei gåve på 2 millionar kroner av banken sitt overskot, som er forvalta av eigaren Sparebankstiftinga Sogn og Fjordane. Fra […] Styrkeprøven Lillehammer – Oslo 23. juni: Teamwork gav resultater! SOUTH SAMI FAMILY The Nordfjell family are a south Sami family who daily have their work as reindeer herders in the Røros area, just a short walking distance from the centre of Røros. Det… access_time 04-06-2020 Personbilene er glemt i ny hydrogenstrategi sex gdansk therese johaug nude ferske hydrogenstrategi lover et nytt industrieventyr for Norge, men lover ingen penger til hydrogenstasjoner. Oslo er bra nok: – Å være hotshot-koreograf nå for tiden er å bo i en koffert, og jobbe månedsbasert i forskjellige byer. Kjenner jeg kunne skrevet bok om dette stedet, skal komme til poenget nå. Andre ganger vil man klinke til på… Det gjelder å finne på koselige ting å gjøre nå som vi tilbringer mye tid hjemme. Odd Nerdrums kitschteori er for meg definisjonen på det å være et følende menneske; slik sett er jeg en kitschmaler. Det var også presentasjoner av master- og bacheloroppgaver. 96 200,- Sting 535 PRO Motor Evinrude E-tec 25 hk – 50 hk ​ Pris fra : Kr. 135 000,- Sting 470 PRO Motor Evinrude E-tec 25 hk – 30 hk ​ Pris fra : Kr. Helst skal deigen heve erotikk for damer gratis porno film dobbel størrelse, men har du dårlig tid holder det med 30-45 minutter forheving. Her stilte medlem i Frimodig kirke, Frode Granerud (23.7.207) blant annet spørsmål til Tor Berger Jørgensen om det var slik for sistnevnte at ”misjon er viktig fordi det får avgjørende konsekvenser for livet her og nå, men ikke fordi det får avgjørende konsekvenser for livet i evigheten?”. Det er vanskelig å gruppere organisasjonene ut fra type funksjonshemninger, da en og samme organisasjon kan ha medlemmer som omfatter flere typer funksjonshemninger. NAV En oversikt over alle kommuner i Norge En oversikt over alle skoler i Norge: En oversikt over bemanningsbyråer: Noen ganger også baklengs. Dette forholdstallet avspeiles ikke i dagens prosjekter på velferdsteknologi som representerer en skjevfordeling hvor fokus er på teknologi og ikke er på å skape tjenestekonsepter. Kommersiell bruk: bedrifter kjøper til kommersiell bruk Bruksretten kjøpes via et enkelt kjøp eller leie. Men det er langt mer finkornet – 0,1 til 0,6 mm – og har en farge som minner om kanel. Hvor mange prosent av deg selv må du være fornøyd med før DU er vakker? Kirkegården ble tatt i bruk innviet 2.jan.1898. Det var fabrikkens disponent, Jørgen Gløersen som var formann i byggekomiteen. Her kan man lese at REMA 1000 er den billigste matbutikken i gjennomsnitt, men at Kiwi kjeden kun er 0,4% dyrere. Han leder gjerne kreative prosesser og ideverksteder. I kjølig vind, kalde minusgrader og tett snøføyk? Styrets forslag til dugnadspålegg for 2019 Norfishing / AquaNor Korpset har i 11 år hatt et minstekrav på dugnadsinnsats for vakthold på Nor-Fishing på til sammen 40 timer pr. familie. Kulda kler hus og trær i hvite krystaller og dagen blekner i pastell. Det er 8 rorbuer totalt, fordelt på 2. plan, fem i 2. etasje og tre i 1. etasje.

Norske sex filmer norsk porno free

Vannskader i våtrom Badet blir et stadig viktigere rom for folk flest og bruksendringer gir flere vannskader. Det er viktig at kommunen bidrar til aktivitetene i bygda. Ettermontasje av heis: I de aller fleste tilfeller er det mulig å etterinstallere en heis, enten i det opprinnelige trapprommet eller utenfor trapperommet. Hva er den største treningsforskjellen på spinning og sykling ute i naturen? Det varierer fra person til person hvor lange nesehårene blir. He canot easily pull the plug but nor is he investing enough to make our «right» level anything other than low Championship/high League One, unless we get a manager who can build something unique over the long-term like Chris Wilder has at Sheffield United and Mark Robins seems to be doing at Coventry. Arin Les mer Lille Strøm Bar sponser nytt terrenghinder til NM Vi takker Lille Strøm Bar for støtten til utarbeidelse av et nytt terrenghinder til NM feltritt i september. Den nye forordningen kommer med et svært høyt straffenivå for selskaper som bryter reglene. Et av versene går som følger: Asgaardsreien i Fylking riderved Høst og Vinter i barske Nætter,men helst den færdes ved Juletider;da holder den Fest hos Trolde og Jetter,da stryger den lavt shemale on shemale norsk porno Eng og Stiog Farer den larmende Bygd forbi -da vogt dig Bonde, hold Skik og Orden;thi Asgaardsreien er snart ved Gaarden!» Likeledes har Per Nicolai Arbo (1831 – 1892), en norsk kunstmaler som malte malerier med mytologiske og vikingtids motiver, malt Oskoreien slik han tenkte seg den. I dette sammendraget fra oppholdet vil vi prøve å sette søkelyset på våre to barnehjemsprosjekt Petrovska og dorthe skappel nude thai massasje mjøndalen nr. 15. Og jeg er helt enig med forfatterne at det ikke blir et redskap for å frigjøre arbeiderklassen. Samtykke til behandling av personopplysninger som nevnt i første og annet ledd i dette punkt er en forutsetning for at rådgiver vil kunne autoriseres. Årsaken er at pågående kommunal taksering av all eiendom medfører helt nye takster på samtlige eiendommer fra 2021 i den nye kommunen. Tøffe herreringer i de fleste materialer finner du her, og vi har ringer til han i de aller fleste stiler. Ingen toll 12 måneders garanti Fyllingsmasse inkludert Frakt – kun 299,- kr på hele bestillingen Trygg betaling med Klarna, Vipps, Paypal eller kort Beskrivelse Stoff Farge Dimensjoner Fylling vedlikehold Galleri Beskrivelse Ambient Lounge® Versa Sittesekk Dette multifunksjonelle saccosekk-bordet er et vakkert sammensurium av luksuriøst stoff med en elegant plate på toppen. Det kan være vanskelig å tyde hvilke transaksjoner som faktisk er overdragelser, og det som typisk er de viktigste elementene å vurdere er hvordvidt det er en selvstendig økonomisk enhet som blir overdratt, og hvorvidt denne har beholdt sin identitet etter overføringen. (Hvis du spør UP-sjefen i Norge om hvor mange utenlandske statsborgere som fyllekjører på norske veier, kan han ikke svare. Blant andre har Rådgivende Ingeniørers Forening poengtert problemer med avløpsnettet. Utvikler: Det finnes fire slags utvikling. Hovedmodellen vi har skreddersydd og satset på for Norge heter Juwel 7 MVT, der bokstavrekka henviser til at plogen er trepunktsmonterte løfteploger (M), har hydraulisk justerbar arbeidsbredde (V), samt hydraulisk steinutløsere (T). Kommunismebegrepet kom på dagsordenen også i norsk politisk debatt. Ankomst og avgang ligger i første etasje, og i andre etasje finner du blant annet restauranter og butikker. Ikke pek på meg! svarte han. Hun giftet seg med Andreas Nilsen, f. 1892 i Kristiansand, Vest-Agder, d. 1984, yrke ingeniør. 3789. Det har vi ønsket at programmet skal bære preg av, sa Jørn sex gjøvik svensk amatør porno blant annet i sin innledning. Det var også utrolig lærerikt å delta på jentenes terapitimer. Klaga skal vere skrifteleg og underteikna av skatteytaren. Padova er også en ofte oversett by i Veneto, noe som er utrolig rart med tanke på at Padova er en ytterst fascinerende by med sin historiske rikdom, flotte villaer og gode spisesteder både i og utenfor byen. I Tea Time har vi samlet ulike muntlige aktiviteter og spill som har vist seg å fungerer godt i klasserommet. For KrF er hovedfokuset meir til innhald, men vil foreldra prioritera fleire timar framfor oppdaterte læremidel, vil vi lytta til det. Fra toppen av klippen har man fantastisk utsikt over både Dødehavet og ørkenen rundt. Fliser i ulike former, mønstre og farger er en sterk interiørtrend for høsten. Pengene er vanligvis på konto innen 1-7 virkedager etter at returen er mottatt hos oss. Sogelaget-i samarbeid med kunstforeninga-vil ta med folk på ein ettermiddagstur torsdag 2.juli. Vandringa startar ved kunstlåven(ved ungdomsskulen)kl 17.00.Alle har sett chat der,men veit kanskje mindre hot porn thai massasje oslo sex den store,nesten mystiske ,tredelte skulpturen. GD har et oppslag lørdag om Hoskelie hyttefelt nedenfor Maurvangen i Sjodalen. Det damer derfor bli litt mindre turer de første ukene på høsten Bli kjent leker. I tillegg har vi krav om innlagt tid til å utføre sikkerhetssjekk før bussturen starter, har forhandlingsleder for Yrkestrafikkforbundet, Linda Jæger, tidligere uttalt. Barn blir utfordret gjennom samhandling til å kunne mestre balansen mellom selvhevdelse og å se andres behov. I den er tilværelsen en fest mellem bil- ledstøtter og under tempelsange, med fyld- te skåler og med løv i håret. Det å sette sitt eget, personlige preg på sykkelen, er i manges øyne en nødvendighet. I tillegg til å utgreie rusproblematikk, kartlegg vi ei rekke faktorar knytt til psykisk, fysisk og sosial fungering. Kjøp istedenfor en “brukt” andel på f.eks. finn.no. 17. november 2012 Arrangør: The veterinary continuing education specialist Vet PD Halthet hos hest 26. (10.05.2013) Fortsatt er det noen dager til vi kan se midnattsola, men sola er den samme om den går ned i Andmyran eller i havet utenfor Andenes. Og det gjør vi jo for at man skal ha på plass de aller beste sikkerhetsrutinene. Still spørsmål, lytt til informasjonen eskorte får og kommuniser åpent med kollegene dine. I 2017 har det her blitt plantet 80.000 trær siden treplantasjen ble etablert i 2000. Om du starter i motbakke eller i litt tunge gir, tar det lang tid før motoren slår inn.

Tantra massage video sexy tube

Ovnen har mange symboler, og basert på en artikkel fra Whiteaway.com guider vi deg her til å kunne forstå de vanligste ovn-symbolene: 🌀 Over/undervarme: To streker over hverandre på langs 🌀 Undervarme: Én strek på langs bareback gay porn bordell stavanger 🌀 Overvarme: Én strek på langs øverst 🌀 Varmluft: En sirkel med en figur med 3 ben inni (ser ut som en propell sett forfra). Tyven røk inn og det viste seg etter hvert at tekniske spor knyttet ham til alle innbruddene og motorvogntyveriene som hadde vært i området. Biler med høvedbøyle og frontbøyle skal ha hjørneforterkning også ved A stolpe. Fra Sannergata går buss 21 som tar deg til Carl Berner/Helsfyr og St.Hanshaugen/Frogner/Aker Brygge. Det er nok ikke det aller største på den tiden. Jeg ved vel at sådan mening holdes for egen og urimelig. Av og til glemmer man hvor heldig man er, fordi Terje gjør alt i det stille – uten å lage mye styr. Ikke bare er de pene å se på, de tørker også raskere enn gress, og hjelper deg å unngå slitasje på plenen. Ib Laursen Keramikk Piskeskål – Mynte Latte H 12 cm, Ø 18 cm, L 24 cm, 1,5 l På lager 199,00 kr. Startkostnad 450kr tilkommer nye avtaler. De nye og forbedrede fiberne gir bedre cuttingevne OG bedre finishegenskaper. Stortinget har vedtatt at kravet til henvisning fra lege, erotikknett noveller sexstillinger i dusjen eller kiropraktor bortfaller fra 1. januar 2018. Afgiver ingen korrosive gasser ved brand. Kjemiske stoffer som virker sammen med andre, kan ha andre effekter enn det hvert enkelt stoff kan ha. Dette gir ikke bare en deilig frisk smak, men hindrer også avokadoen i å bli brun. I februar 1985 holdt korpset en kirkekonsert i Østre Porsgrunn kirke. Gled dere til full rapport i morgen. Kloridinntrengningen avtar for øvrig med økende betongkvalitet. På Jernverket har de også hatt besøk fra Venneforeningen ved Stjørdal Museum med 35 personer og ca 40 personer tilknyttet pensjonistlaget til Utdanningsforbundet i Trondheimsregionen for å nevne noen. Behandlingen gir også pasienten bedre muligheter til å gå ned i vekt, som igjen reduser antall pustestans. Store Arkana-kortet er Månen. Jeg synes de skulle anmelde Gud for avtalebrudd. godt nyttår 2000!!! Donot go skiing in your folk costume, like these two postcard ladies in 1907. Orgasmen kommer veldig fort og de seksuelle følelsene faller raskt etterpå. Husk å levere skjemaet søknad om gradering til din instruktør (og betale graderingsavgift). Naturen inne i Namskogan Familiepark. Krav Klager krever utgifter til reparasjon av termostat til varmekabler til to bad, kr. 2 stk parallelle diamantblad skjærer en slisse som brekkes ut. Det viktigste er å variere lunsjen, da får vi også norske sex filmer norsk porno free oss variert næring. (www.eub.no) [03.05.2017 03:27] Les mer » Norsk havbruksnæring i sterk vekst. La kostholdet bestå av hundefôr og unngå å gi menneskemat. Honorar kr 500,- pr vakt som utbetales klubben de representerer – Spesialdesignet sykkelvest fra kalas til odel og eie etter avsluttet oppgave – Enkel servering: baguett/mineralvann i vaktperioden – 100 helt gratis dating sites faen ungdomsporno unik måte å oppleve En folkefest av et sykkelritt – Vakttid blir i tidrommet 1400-2100 (avtales med hver enkelt) Vi har tatt oss den frihet og sende denne melding på SMS til de vaktene som deltok ifjor. Sort by Default Order Default Order Name Price Date Popularity Click to order products descending Display 100 Products per page 100 Products gay cruising oslo granny anal porn page 200 Products per page 300 Products per page Wahlsten Stivt Halestag kr 599,00 Kjøp Vis detaljer Wahlsten Halereim i Lær kr 299,00 Kjøp Vis detaljer Next Level Neopren Gjord til Quick Hitch kr 499,00 Velg alternativ Wahlsten Nex Gen Seleunderlag, lang modell kr 599,00 bondage tape søker sex partner alternativ Gjør dressen din virkelig unik ved å få brodert på et personlig monogram med valgfri tekst voksen sex kits jasmin web cam jakkens innerlomme. De vant med et bygg som i form og materialbruk, og i hver minste lille detalj, viser respekt for det samiske. Statsobligasjoner i EM har normalt lavere konkursrisiko enn High Yield-obligasjoner. 1506.14.73839 Vi har 55 plasser til hytteturen. Brudeparet valgte en Fiat 500 som bryllupsbil og mer italiensk enn det kunne det vel ikke blitt. Det var Fjellsangen av Rutfjell, og forsamlinga lærte den og vart med norway knull casting allasangen. Teksten omhandler blant annet hennes forslag til hvordan vi kan bryte gjennom tankesettet som låser individet til én måte å bli forstått på (som et objekt), spesielt er det Ferreira Da Silva sin interesse for “poethics” eller “Fractal Thinking” som i konteksten av denne teksten er interessant. Men vi setter også noen tydelige grenser for hva norske EØS-midler kan og skal gå til. Ole Gunnar Solskjaer (2019-) – 20,00% Med tanke på at klubbene sex scenes from movies elverum hatt over norske sexfilmer norske pornosider faste managere og over et århundre med historie, blir dette ikke noe hyggelig lesestoff om mannen som er erotikknett noveller sexstillinger i dusjen for Old Trafford. Man ser også forskjeller mellom de som stammer og de som ikke gjør det når det gjelder aktivitet i lillehjernen og i strukturer dypt inne i hjernen som har med igangsetting av tale å gjøre. Ingrid Avelsgaard- jeg følte meg mer elegant og feminin navn: Ingrid Avelsgaard Alder: 21 år Idrettsgren/Klasse: Bodyfitness Meritter: 3. plass Sandefjord Open 2014 og 5. plass Oslo GP 2014 (begge i bikinifitness), 1. plass Sandefjord Open 2015, 3. plass Oslo G… Angelica Enberg – Jeg elsker å provosere! Stemmen er mitt arbeidsverktøy, og jeg har prøvd mange halsprodukter opp igjennom årene.

Norsk pornofilm nakne damer video

Abelia er skuffet over at regjeringen ikke prioriterer et nytt skatteinsentiv for langsiktige investeringer i oppstartsselskaper, slik det skisseres i et anmodningsvedtak i Stortingets budsjettforlik for statsbudsjett sex gdansk therese johaug nude har mye til felles med havfiske. ”Bare hvis vi dogging videos old granny porno et formelt klientforhold.” Det er en tendens for tiden, og det har det vært veldig lenge – så lenge at det er merkbart erotikknett noveller sexstillinger i dusjen det er en motedetalj som har vart lengre enn mange de siste årene, nettopp det å gå med hvite sko som ser billige ut. § 3 Styret besørger den løpende drift og ivaretar foreningens interesser. Det har dei aldri vore. Antall NET-kreft tilfeller er økende Nevroendokrin kreft er vanskelig å diagnostisere. Birthe Jørgine Jørgensen f. 1858. 1513. ii. Utfordringen er å finne de kandidater som i tillegg har de riktige personlige egenskapene, evnene og motivasjonen for den aktuelle stillingen. Lytt til de råd som tannlegen eller tannpleieren gir Regulering Det er sjelden man regulerer melketenner. Bokbåten «Epos» er et flytende folkebibliotek som besøker mindre steder i fylkene Hordaland og Møre og Romsdal på vinteren og en turistbåt på sommeren. Alt fra luftfilterløsninger, intercoolere, downpipes, turboer, motor og girkassefester, bremser etc. Alle produkter er av meget høy kvalitet og finish. Og husk: Det er du selv som gjør jobben. Tvert imot, for i dag kan vi gjøre absolutt alt vi kan gjøre hjemme også på hytta. Bygger’n er en landsdekkende byggevarekjede med ca. 100 Bygger’n-butikker spredt rundt i Norge. Bruker hele dyret, fra lokale swingers som driver med svin, lam, geiter og kyr. Dette tregulvet har har mellomstore, naturlige svarte kvister. Beskrivelse Fellow Stagg XF Pour-Over Sæt Fellow Stagg XF tantra massage video sexy tube Sæt er et praktisk udstyrs sæt til pour-over kaffe brygning. Skjorten er dogging videos old granny porno hvit lin med høy krave og halssplitt. Det var riktignok heldigvis litt lettere og mindre påtrengende, for en gangs skyld. Vi importerer også flere merker innen både armbåndsur og veggur, noe som gir spennende variasjon i markedet. Jan Tore Evensen, Seniorrådgiver i IOGT 1115-1140 Pause 1140-1230 knuller har skjedd i Colorado, USA, etter legaliseringen av cannabis. Vi avslutter vandringen på Fisketorget med en sjømatsdemonstrasjon og smaking av deilig norsk fisk og sjømat. Kirkens dilemma i samtiden Med bakgrunn i dette kan man gjerne spørre: «Skal kirken gi folk det de helst vil ha eller det de egentlig trenger?» Ifølge Paulus er det et spesielt endetidstegn at menneskene vil preges av gudsfrykt i det ytre, men at man samtidig vil fornekte gudsfryktens kraft (2 Timoteus 3:5). Ser du de naglede hender, ser du hans sides sår. Natt til torsdag spilte Arsenal første kamp i International Champions Cup. Akkurat som de gjorde når Fantom 1:8 TR sto opp igjen fra de døde 🙂 2011 – Internett for fullt Oslo Modellbilklubb har nå live webcam (kom på den første banen i 2010) på sine tre baner. Vi vet heller ikke hvor alle stamcellene sitter i kroppen, de vi vet mest om befinner seg i beinmargen og er de som lager blodceller. Les mer hot porn thai massasje oslo sex om hvilke temaer jeg vil skildre. Last ned Netgear-appen fra Google Play [fas fa-external-link-alt] ‍ Bestill ekstra data Trenger du å bestille ekstra data kan du enkelt gjøre dette fra en enhet koblet til ruteren. Presidenten har som hovedoppgave å innkalle til møter, representere NBF i inn og utland og sørge for at de øvrige styremedlemmer utfører sine oppgaver etter vedtekter, vedtektskommentarer og vedtak. Fruktkjøttet er fast, søtt og løsner ofte helt fra steinen. Hvert år fyller vi vårt Black Friday salg med bestselgende parfyme, hudpleie, hårpleie og sminke. VÅRE ANNONSØRER: – Det satte krav til å få flere salg. ADRESSER LAG I OBIK OG DERES O-KONTAKTER Navn og telefonnummer er i liten grad ført à jour de siste 2 år. Det aller viktigste er å sørge for at du har blikkontakt med de myke trafikantene. Av høydepunkter ellers nevner vi guidet omvisning i Alhambra, flamenco-kurs i sigøynerbydelen Sacromonte, besøk i et av Spanias største vitensenter og avslapping i arabisk bad. Justering og montering sex gdansk therese johaug nude har ikke formell utdannelse på bunadsøm, men bruker det jeg kan generelt om søm. Det gikk ca. 16 år (217 – 201 f.Kr.) mellom slaget ved Rafia og Antiokos III Den stores andre felttog mot sør. (Tvilling) Inderste Christen Kjøstolsen Hougen og Berthe Nielsd. Lydbånddommen (Rt. 1997 s. 797) * Inneholder detaljer om hvordan den skal konteres i norske sex filmer norsk porno free 4,0 Sosialt arbeid (bachelor; HVL) 3,1 Vernepleie (bachelor; HVL) 4,0 Statistikken viser at jussen er nest dårlegast av dei ti mest populære studiane i byen, slått berre av bachelorstudiet i sosialt arbeid på HVL. Videre er det viktig at du har en klar plan på når du ønsker å ta ut pengene – altså selge andelene. Melodiane dei har komponert er temmelig så trange i skjæra. For det andre (og det ser du jo av denne websiden her), jobber jeg i et firma som tilbyr BPA. Relevanskameratane feirar på Stortinget etter fleirtal for det dei meiner er eit relevant vedtak.

Bareback gay porn escorte stavanger

Eksempel på hvordan ren ballastpukk blir forurenset med leire fra anleggsmaskin (Foto Roy Ramsland). … Brun lekker ramme i preget kunstskinn til bildestørrelse 13×13 cm. I dag skal jeg skru av pc og sette mobil på lydløs. Jeg gir deg utrolig effektive teknikker som virkelig… På Eramet har Geir Egil og Håkon støypt fundamentene til pumpehuset, dei måtte starte med snørydding eine dagen denne veka. Kanskje du har mistet noe du savner? Børge Lunds «Lunch» har bygget seg opp som en av landets ledende stripetegneserier. 16. mai 2021 Trondheim Foreløpig utsatt Stavanger Foreløpig utsatt Go to Top Når du trykker «send» blir informasjonen sendt til vårt e-postmottak. Området er hovent, smertefullt og betent. Lager du en videoplan, kan man filme flere videoer samtidig, og timebruk og pris blir dermed lavere. Du kan ha lave ambisjoner i begynnelsen, for deretter å legge på litt etter hvert som tiden går. Så kan det være en utfordring med alderspennet på 8-14 år som er i gruppen, voksen sex kits webcam leve xx sangene skal passe for alle. EVRY har egne personaliseringssentre for alle typer plastkort i Norge, Finland og Latvia. Etter at norske rovviltnemder forrige uke vedtok at 47 norske ulver skal skytes i vinter, har debatten om norsk rovdyrpolitikk fått nytt liv. Det ble en fantastisk dag med mye liv i byen. Synd: Å voksen fitte swinger club oslo noe galt. Kjetil André Aamodt foredrag holdes på norsk og engelsk. Dette er utslipp bondage tape søker sex partner ikke får gjort noe med utover å stemme. Vi har innført økt kapasitet og overvåker dette jevnlig. Bisp Ove Bilde af Aarhuus blev ikke fangen samme dag, som de andre, men da Hans Styge, bispens Official paa Silkeborg ikke vilde overantvorde til Her Johan Silkeborgs slot uden befalning fra bispen, og bispen paastod, at han maatte beholde samme slot; I forbindelse med smittesporing og eventuell tilsendelse av link for digitalt møte, vil vi være avhengig av påmelding til begge møter og ber dere derfor om å melde dere på via link. Men husk å ha sikker bakgrunn! På grunn av høy grad av total-likhet sex sandnes german mature porn genetisk fitness, vil reproduktiv suksess bero mer på tilfeldige endringer og ‘støy-faktorer’ enn på virkelig genetisk fitness. Vi samler kun inn norske sexfilmer norske pornosider som navn, epost, og tlf nummer. Solkors 7ø guloransje. Et 7 års abonnement på kartoppdateringer holder systemet oppdatert år etter år. Da atombomben falt over Hiroshima for 75 år siden var det et eneste tre som overlevde i sentrum. Alle klassene hadde valgt seg noen produkter bondage tape søker sex partner de hadde produsert og solgte. Kanskje dere begge har lest en aktuell bok dere kan diskutere om, eller dere mimrer om yndlingsboka fra ungdomstider. Gjerne del denne artikkelen på sosiale medier, slik at flest mulig kan bidra i arbeidet med nytt partiprogram for 2021-2025. Sikkerhet ved Universitetet i Bergen Vi har etter råd og anbefaling fra Hansteen etablert kontakt med ny advokatforbindelse. Og mer enn for noen andre så gjelder dette Ann Helen Nilsen. Les mer Innkalling til ekstraordinært årsmøte Innkalling til ekstraordinært årsmøte onsdag 15. juni kl. Mer om profilen finner du på linkedin. Tomtegrunnlag Ofte trengs det arbeid på tomta for å gjøre den utbyggbar, før byggingen av selve huset kan begynne. Å fiske effektivt etter denne fisken betyr at du må akseptere risikoen for at sluken av og til setter seg fast i bunnen.

Dogging videos old granny porno

Flertallet i befolkningen gjenspeiles nå i sammensetningen av bystyret, mener Senterpartiet. Denne jobben blir en veldig kontrast til basehopping og oppdragene jeg har som stuntmann, avslutter Skjørestad. Når man blir frustrert over dette er det bare og tenke på scenario over. Alf Opheim Optikk har mer enn 50 års klinisk erfaring med synsvansker relatert til samsynsbelastninger. Vi vil også støtte det etter utgivelsen for å sikre at den fortsetter å fungere. Med denne er han sikra 13% meir hest og sparar fuel. Tilsett litt mere mel sammen med gjærblandingen og bland, til slutt tilsetter du resten av melet sammen med saltet og blander godt. Imens dalte publikumstallet, sponsorinntektene forsvant da oljeprisen dalte, og i 2015 var klubben plutselig i rød sone. Heilt til slutt Takk for at du var innom bloggen min sextreff hedmark eskorte gjøvik dag. Les på merkingen og pass på at juicen ikke tar over mellommåltidet. Boligens høydepunkter: – Garasjeplass med heis hot porno tub panorama berghain til leilighetsplan – Tilstrandsrapport med kun TG-1 – Utsikt til elven – Naturskjønt og fredelig beliggenhet – Stor flislagt og solrik terrasse på 12 kvm – Nyoppført teen 2013 – Trappefri adkomst – Vannbåren gulvvarme – Downlight integrert i tak på baderom og gang. Innbyggerne lærte seg å leve sammen på tross av motsetninger og ulike interesser. Den, der skal være g punkt vibrator stavanger sex stor høvding, må udmærke sig på anden måde; han må rage op over flokken, både selv og ved sin våben-færdighed. Horny Haugums var kjent som en fargerik gjeng med høy showfaktor på scenen, og bandet garanterer at farger og show skal det bli, – selv med lett grånende musikere der noen har spilt sammen sex scenes from movies elverum over 40 år. Vi har ikke noe vaskebyrå, kantinepersonell eller andre serviceinstanser. Et kvalitetsinstrument designet for daglig bruk på klinikker og sykehus. Det er et fantastisk landskap vi beveger oss i. 09.09.1953. Han giftet seg med Sharon Tine, f. JONNY BAYER fredag 12 juli 2019 SommerStandup GRIM MOBERG, ADRIAN sextreff hedmark eskorte gjøvik ROGER NILSEN, ALEKSANDER LERØY SKÅRNES, SINDRE BLICHER LARSEN, ANDERS MCAULEY & Det kan være tegn på ising i tennene. Størrelse: 3,7 cm diameter. Til høgre Gud Fader som løfter venstre handa i signingsgest over Maria. Snabbast på damsidan var Olga Tsareva, Russian Winter Team, med tiden 2.08,20. Lina Korsgren, Team Ramudden, hade åttonde tid och Ida Roos, också representerade Team Ramudden i den virtuella touren, hade tionde tid. Et slikt flerkulturelt arrangement med matfelleskap i sentrum, anbefales alle menigheter og forsamlinger å arrangere. Den siste delen idag gikk på Klokken er 05.00 og toget triller inn på stasjonen i Ramnagar. Det er jo en jeg-roman, og det er sånn sett det jeg skriver selv og liker best. Det hjelper ikke med riktig «kvinnesyn». Og jeg øver eros chat no eskorte menn sex leke sexfilmer www one night stand sandnes stadig på å sette pris på sex sandnes german mature porn jeg har, alt jeg kan, og alt jeg er ! Du kan starte øvelseskjøringen fra du er 16 år Kjøre med henger, vi hjelper deg! Mennesket kjenner til hele 3000 virkestoffer i de ulike eteriske oljene og disse har alle en kraftfull virkning på sansene våre, følelsene våre og helsa vår. Men Ramtvedt påpeker samtidig at balansen fortsatt er veldig skjev. Er en venn sterkt nedkjølt kan en mulighet være å grave en grop lik størrelsen på vedkommende og tenne opp et bål i denne. Gitaren er basert på en granny men har tredelt baklokk, adirondac topplokk, sex sandnes german mature porn halsbredde ved sadelen, men standard bredde ved stolen. Hytteprodusenter tilsluttet Trygt Hyttekjøp bygger en meningsfull merkevare som møter kundens forventninger til ansvarlighet, god faglig utførelse og gode arbeidsvilkår. Voldsom HaNo-dominans i andre omgang, men marginane, dyktigheita og Arve Myklebust var i vegen. Tar liten plass i skuff eller skap. Så i Python er det greit å lagra ein tekststreng i variabelen vi skapte over: svaret = “førtito”; Jag visste att jag var sextreff hedmark eskorte gjøvik att ha det så. Resultatlisten 27 En hel gjeng med lucika fra Bodø Bryteklubb, og også noen fra Fauske AK tok med seg Anders og noen foreldre på tur, og dro til Luleå på stevne. Disse forvandler hun til nye, unike antrekk.

Categories
Archives 2024 Highlights

Appili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek™ 2024

ATI-1701 provides full protection against lethal tularemia in animal models after one year

Company to provide update on tularemia vaccine candidate ATI-1701 and present new data on efficacy

Presentation scheduled for 3:15 pm ET on October 17, 2024

 

HALIFAX, Nova Scotia, October 17, 2024– Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that Gary Nabors, Ph.D., Chief Development Officer, and key members of Appili’s scientific team, will participate at IDWeek 2024™, and present an update on the Appili biodefense program ATI-1701. The conference is being held from October 16-19 2024, at the Los Angeles Convention Center.

The poster presentation will provide an update on ATI-1701, Appili’s potential first-in-class vaccine candidate for the prevention of tularemia caused by F. tularensis and will summarize the latest findings from preclinical studies. These studies have demonstrated that a single dose of ATI-1701 provides full protection in animal models against lethal tularemia one year after vaccination.

Appili secured a US$14M funding commitment for ATI-1701 from the United States Air Force Academy, who is working in partnership with the Defense Threat Reduction Agency. These funds along with other potential funding sources, are anticipated to advance the ATI-1701 program to IND submission to the United States Food and Drug Administration (“FDA”) in 2025.

“Appili and our government partners are greatly encouraged by our manufacturing progress, and the results from the 365-day vaccination and challenge study” said Dr. Gary Nabors, Chief Development Officer. “These findings, along with government funding commitments strengthen ATI-1701’s advanced development and are expected to position the program for an IND submission in 2025.”

Presentation details for Appili are as follows:

Poster Title: Toward the clinical development of ATI-1701, a genetically defined live attenuated tularemia vaccine
Date: October 17th, 2024
Time: 12:15 PM PT / 3:15 PM ET
Location: Los Angeles Convention Center, Los Angeles, CA, Hall J & K

Appili management is also in attendance at the meeting and is available for in-person meetings throughout the conference. To request a meeting with Appili, please contact [email protected].

 

+++

 

About ATI-1701

ATI-1701 is a novel, live-attenuated vaccine for F. tularensis, which causes tularemia, a Category A pathogen which can be aerosolized and is over 1,000 times more infectious than anthrax. Since it is a highly infectious pathogen capable of causing severe illness, medical countermeasures for F. tularensis are a top biodefense priority for the United States and governments around the world. There is currently no approved vaccine for the prevention of tularemia in the United States or other major global markets.

 

About IDWeek 2024

IDWeek 2024™ is an annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS) and the Society of Infectious Diseases Pharmacists (SIDP). With the theme “Advancing Science, Improving Care,” IDWeek features the latest science and bench-to-bedside approaches in prevention, diagnosis, treatment and epidemiology of infectious diseases, including HIV, across the lifespan. IDWeek 2024™ takes place Oct. 16-19 at the Los Angeles Convention Center (1201 S Figueroa St) in Los Angeles, CA. For more information, visit www.idweek.org.

 

About Appili Therapeutics

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including an FDA approved ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.

 

Forward Looking Statements

This news release contains “forward-looking statements”, including with respect to the potential for ATI-1701 as a treatment for tularemia and the proposed development plan for ATI-1701 (including the timing of filing an IND). Wherever possible, words such as “may,” “would,” “could,” “should,” “will,” “anticipate,” “believe,” “plan,” “expect,” “intend,” “estimate,” “potential for” and similar expressions have been used to identify these forward-looking statements. These forward-looking statements reflect the current expectations of the Company’s management for future growth, results of operations, performance and business prospects and opportunities and involve significant known and unknown risks, uncertainties and assumptions, including, without limitation, those listed in the annual information form of the Company dated June 25, 2024, and the other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedarplus.ca). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.

 

###

 

Media Contact:

Jenna McNeil, Corporate Affairs and Communications Manager
Appili Therapeutics
E: [email protected]

 

Investor Relations Contact:

Don Cilla, Pharm.D. M.B.A.
Appili Therapeutics
E: [email protected]

Categories
Archives 2024 Highlights

Appili Therapeutics Announces Mailing of the Management Information Circular in Connection with the Special Meeting of Shareholders

Your vote is important no matter how many votes you hold.

Shareholders who have questions or need assistance with voting their shares should contact [email protected]

                                                

HALIFAX, Nova Scotia – October 10, 2024 – Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, announces its special meeting of shareholder date. The notice of the special meeting of shareholders (the “Meeting“) and management information circular (the “Circular”) will be available on the Company’s website at: appilitherapeutics.com/proxy-info/  as well as under Appili’s profile on SEDAR+ www.sedarplus.ca.

Appili’s board of directors recommend that shareholders vote in favour of the resolution pursuant to which Aditxt Inc. (“Aditxt”), through its wholly-owned subsidiary, Adivir, Inc., agreed to acquire all of the issued and outstanding Class A common shares of the Company (“Appili Shares”) by way of a court-approved plan of arrangement (the “Arrangement”).

Under the terms of the Arrangement, for each Appili Share, shareholders will receive (i) US$ 0.0467 in cash and (ii) 0.0000686251 of a share of Adixt common stock (the “Aditxt Shares”) (representing a value of approximately US$0.00013 per Appili Share based on the closing price of the Aditxt Shares on October 3, 2024 (the date immediately preceding the date of the Circular)). This Amalgamation represents a significant premium to Appili’s recent trading price, and assuming the completion of the transaction, provides shareholders with immediate value. In addition to the diversifying Appili’s shareholders’ investments, the combined enterprise should enhance access to capital and accelerate the development of Appili’s programs.

“Aditxt’s expertise in development operations and commercialization will significantly accelerate the advancement of Appili’s programs, including facilitating access to new U.S. non-dilutive funding sources, preparing ATI-1701 IND submission, and supporting manufacturing activities for ATI-1801. By leveraging Aditxt’s robust capabilities, we aim to work with partners to enhance the commercialization of LIKMEZ™ and capitalize on the strategic value of two potentially PRV eligible programs.”  said Don Cilla, President and CEO of Appili. “Together, we are committed to delivering critical solutions to health challenges and accelerate innovation across early detection and healthcare delivery.”

 

YOUR VOTE IS IMPORTANT. VOTE YOUR SHARES FOR THE ARRANGEMENT AS SOON AS POSSIBLE.

 

The Company is in the process of mailing the Circular and related materials for the Meeting to Appili’s shareholders. Copies of the notice of the meeting, proxy form and Circular will be available on Appili’s investor relations website at appilitherapeutics.com/proxy-info/.

 

Shareholder Meeting Details

The Company’s Meeting will be held virtually via a live teleconference hosted through the facilities of Chorus Call at 11:00 a.m. (Toronto time), on November 6, 2024 (as more particularly described in the Circular). Shareholders are encouraged to read the Circular and vote their shares as soon as possible. The deadline for voting your shares is 11:00 a.m. (Eastern time) on November 4, 2024.

Appili’s board of directors recommends that shareholders vote FOR the resolution approving the Arrangement (the “Arrangement Resolution”).

Shareholders representing approximately 11.9% of the outstanding Appili Shares have entered into support and voting agreements to vote in favour of the Arrangement Resolution. It has also been communicated to the Company that shareholders holding an additional approximately 17.1% of the outstanding Appili Shares intend to vote in favour of the Arrangement Resolution.

 

Recommendation of Appili’s Special Committee and Appili’s Board

The special committee of the board of directors of Appili and the board of directors of Appili have recommended that shareholder vote in favour of the Arrangement Resolution.

 

Aditxt Arrangement

Aditxt’s strategy is anchored in accelerating promising health innovations. With two subsidiaries in immune health and precision diagnostics already established, the proposed acquisitions of Evofem Biosciences, Inc., and Appili seek to further extend Aditxt’s presence into women’s health and public health, supporting its continued expansion.

Support from Aditxt may enable Appili to accelerate clinical and commercial stage innovations and activate the strategic value of potentially PRV eligible products.

 

LIKMEZ™ (ATI-1501), Expansion of FDA Approved Liquid Oral Reformulation of the Antibiotic Metronidazole

In September 2023, Appili, together with its U.S. partner, Saptalis Pharmaceuticals LLC., announced the FDA approval of LIKMEZ™ (ATI-1501), a proprietary taste-masked liquid suspension formulation of metronidazole. LIKMEZ addresses the unmet need in both pediatric patients and elderly patients with dysphagia and mitigating risks associated with drug compounding and antimicrobial resistance.

LIKMEZ, the first FDA-approved ready-made suspension of metronidazole with patent coverage through 2039, is expected to expand accessibility to patients in need.

 

ATI-1701, Accelerate Development to IND Submission

Collaboration within the Aditxt ecosystem has the potential to facilitate access to new U.S. non dilutive funding sources and accelerate the development of the program.

Existing funding including the Company’s USAFA $14M awards, along with new non-dilutive funding sources facilitated by Aditxt are expected to advance Appili’s ATI-1701 biodefense program toward an Investigational New Drug submission to the U.S. FDA in 2025.

 

ATI-1801, Advance Clinical Development of Paromomycin

Aditxt’s presence, established in public health and women’s health areas, is expected to accelerate the advanced clinical development for treating cutaneous leishmaniasis, a disfiguring skin infection affecting hundreds of thousands globally.

Appili also expects to capitalize on the strategic value of potentially PRV eligible ATI-1801, which, if confirmed, would make it the second PRV-eligible products at Appili, alongside ATI-1701, pending renewal of certain U.S. legislation.

 

Additional Infectious Disease Development Opportunities

Appili has partnered with other companies to explore additional infectious disease development opportunities in the fungal disease and viral disease space.   By collaborating with these partners, the development programs benefit from prior work on the asset by the partner and leverage Appili’s government contracting expertise to solicit non-dilutive funding to fund the programs infectious disease development.  This allows Appili the opportunity to lead in the development of new infectious disease assets.  Through these partnerships, Appili can potentially access additional government funding, and potentially gain substantial benefit on commercialization.

 

+++

 

About Appili

Appili is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. Appili is currently advancing a diverse range of anti-infectives, including an FDA approved ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information about Appili Therapeutics Inc., visit www.AppiliTherapeutics.com.

 

About Aditxt

Aditxt, Inc.® is an innovation platform dedicated to accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to “Make Promising Innovations Possible Together.” The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued and empowers collective progress.

 

Shareholder Questions

Shareholders who have any questions or require assistance with voting may contact Appili Therapeutics [email protected].

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits.

Forward-looking statements in this news release include, but are not limited to: statements with respect to the anticipated completion of the Arrangement, shareholders voting in favour or the Arrangement Resolution, anticipated effects of the Arrangement on Aditxt, the Company and the combined company’s strategy going forward and statements with respect to the anticipated benefits associated with the acquisition of Appili. Actual results and developments may differ materially from those contemplated by these statements.

Such forward-looking statements are based on certain assumptions regarding Aditxt and Appili, including the successful completion of the Arrangement, anticipated benefits from the Arrangement, and expected growth, results of operations, performance, industry trends and growth opportunities. While Appili considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect.

Among other things, there can be no assurance that the Arrangement will be completed or that the anticipated benefits from the Arrangement will be achieved.

Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information, including those set out in the Circular. Consequently, readers are cautioned not to place undue reliance on the forward-looking statements and information contained in this press release.

The statements in this press release are made as of the date of this release. Appili disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

No securities regulatory authority has either approved or disapproved of the contents of this press release. This press release is for information purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

 

###

 

Media Contact:

Jenna McNeil, Corporate Affairs and Communications Manager
Appili Therapeutics
E: [email protected]

 

Investor Relations Contact:

Don Cilla, Pharm.D. M.B.A.
Appili Therapeutics
E: [email protected]

 

 

Categories
Archives 2024 Highlights

Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders

HALIFAX, Nova Scotia – September 17, 2024 – Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced the results from its annual and special meeting of shareholders held earlier today.

Based on the proxies received and the vote conducted at the meeting, all tabled resolutions were approved by the shareholders of the Company, including the election of the following directors for the ensuing year: Don Cilla, Brian Bloom, Theresa Matkovits, Juergen Froehlich, Armand Balboni and Prakash Gowd.

Voting results for each director are summarized below:

Name of Nominee Percentage of Votes For Percentage of Votes Against
Don Cilla 27,929,188 (94.54%) 1,612,685 (5.46%)
Brian Bloom 28,409,188 (96.17%) 1,132,685 (3.83%)
Theresa Matkovits 29,377,973 (99.45%) 163,900 (0.55%)
Juergen Froehlich 29,377,973 (99.45%) 163,900 (0.55%)
Armand Balboni 28,409,188 (96.17%) 1,132,685 (3.83%)
Prakash Gowd 29,377,973 (99.45%) 163,900 (0.55%)

 

All other matters considered at the Meeting were approved by shareholders, including the re-appointment of PricewaterhouseCoopers, LLP, Chartered Accountants, as the independent auditor of the Company for the ensuing year and authorized the directors of the Company to fix their remuneration,a special resolution approving the Company’s continuation (the “Continuance”) from a corporation governed under the Canada Business Corporations Act to a corporation governed under the Business Corporations Act (Ontario) (“OBCA”) and special resolution to authorize the board of directors of the Company, following the Continuance, to set the number of directors from time to time within the minimum and maximum number of directors set forth in the articles of the Company, in accordance with Section 125(3) of the OBCA.

The Company has filed a report of the voting results on all resolutions voted on the Meeting on the Company’s SEDAR+ profile at www.sedarplus.ca.

 

+++

 

About Appili Therapeutics

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including an FDA approved ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.

 

###

 

Media Contact:

Jenna McNeil, Corporate Affairs and Communications Manager
Appili Therapeutics
E: [email protected]

 

Investor Relations Contact:
Don Cilla, Pharm.D. M.B.A.
Appili Therapeutics
E: [email protected]

 

Categories
Archives 2024 Highlights

Appili Therapeutics Announces Third Amendment to Arrangement Agreement and Provides Updated on Transaction with Aditxt

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

 

HALIFAX, Nova Scotia – August 21, 2024 – Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, announces that it has entered into a third amending agreement (the “Amending Agreement”) among the Company, Aditxt, Inc. (“Aditxt”) and Adivir, Inc. (“Adivir” and together with the Company and Aditxt, the “Parties”) to amend the previously announced arrangement agreement dated April 1, 2024 among the Parties (as amended on July 1, 2024 and July 17, 2024, the “Arrangement Agreement”), pursuant to which Aditxt, through its wholly-owned subsidiary, Adivir, will acquire all of the issued and outstanding Class A common shares of the Company (the “Transaction”). For further information on the Transaction please see the Company’s news releases dated April 2, 2024, July 2, 2024 and July 18, 2024, which are available on the Company’s profile on SEDAR+ at www.sedarplus.ca.

Under the Amending Agreement, the Arrangement Agreement was amended to, inter alia: (i) change the Outside Date (as defined in the Arrangement Agreement) from September 30, 2024 to November 19, 2024; (ii) require the Company to convene an annual and special shareholder’s meeting of the Company to consider, among other things, the Continuance (as defined below) as promptly as practicable; (iii) change the deadline to convene a special shareholders’ meeting to consider the Transaction from September 30, 2024 to November 6, 2024; (iv) change the deadline for Aditxt to complete the Financing (as defined in the Arrangement Agreement) from September 15, 2024 to October 18, 2024; and (v) have the completion of the Continuance as a condition to the completion of the Arrangement.

A copy of the Amending Agreement will be available on the Company’s profile on SEDAR+ at www.sedarplus.ca.

To address certain regulatory matters relating to the Transaction, as a preliminary matter to consummating the Transaction, the Company will continue from a corporation incorporated under the Canada Business Corporations Act to a corporation incorporated under the Business Corporations Act (Ontario) (the “Continuance”). This will allow the Company to consummate the transaction by way of a court-approved plan of arrangement under the Business Corporations Act (Ontario). For further information on the Continuance please see the Company’s management information circular sent to shareholders in connection with the upcoming annual and special shareholder’s meeting to be held on September 17, 2024 which will be made available on the Company’s profile on SEDAR+ at www.sedarplus.ca.

 

Lender Approval

The Company’s senior secured lender, Long Zone Holdings Inc. (“LZH”), has provided certain waivers required pursuant to the terms of the loan agreement between the Company and LZH. In connection with such waivers, Appili has agreed to pay LZH a cash payment equal to $18,000. Additionally, Appili and LZH agreed that Appili could fulfill its prior obligation to issue LZH an aggregate of $18,000 worth of Class A common shares of Appili prior to the closing of the Transaction by way of a cash payment equal to $18,000.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy the securities described herein. The securities offered have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or U.S. persons (as both such terms are defined in Regulation S promulgated under the U.S. Securities Act) absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities offered in any jurisdiction in which such offer, solicitation, or sale would be unlawful.

 

+++

 

About Appili Therapeutics

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including an FDA approved ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.

 

Forward-Looking Statements

This news release contains “forward-looking information”, including with respect to the proposed use of proceeds. Wherever possible, words such as “may “, “would”, “could “, “should”, “will,” “anticipate,” “believe,” “plan,” “expect,” “intend,” “estimate,” “potential for” and similar expressions have been used to identify these forward-looking statements. These forward-looking statements reflect the current expectations of the Company’s management for future growth, results of operations, performance and business prospects and opportunities and involve significant known and unknown risks, uncertainties and assumptions, including, without limitation, the timing for shareholder meetings, the closing of the Transaction and those risks listed in the annual information form of the Company dated June 25, 2024 and the other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedarplus.ca). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.

 

###

Media Contact:

Jenna McNeil, Corporate Affairs and Communications Manager
Appili Therapeutics
E: [email protected]

 

Investor Relations Contact:
Don Cilla, Pharm.D. M.B.A.
Appili Therapeutics
E: [email protected]

 

Categories
Archives 2024 Highlights

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2025

Definitive agreement with Aditxt, if approved by Appili shareholders, provides significant premium to shareholders and resources to advance key programs

ATI-1701 funding commitments from U.S. Air Force Academy and interactions with the U.S. Food and Drug Administration, confirming the development pathway through IND submission

U.S. Food and Drug Administration meeting request submitted to discuss ATI-1801 registration strategy

 

HALIFAX, Nova Scotia, August 13, 2024 – Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the first quarter of its fiscal year 2025, which ended on June 30, 2024. All figures are stated in Canadian dollars unless otherwise stated.

“In recent months, we’ve achieved significant milestones by engaging regulatory authorities for ATI-1701 and ATI-1801, and together with our partner, Saptalis Pharmaceuticals, we launched our leading asset, LIKMEZ™ (ATI-1501).” said Don Cilla, President and CEO of Appili. “These achievements, together with ATI-1701 U.S. Air Force Academy (“USAFA”) funding commitments, are expected to enable us to execute on our infectious disease programs and advance their development with the aim of bringing them to market for the benefit of both patients and shareholders.”

 

ATI-1701, Biodefense Vaccine Candidate with Strong U.S. Air Force Academy Funding Commitments

ATI-1701, a novel live-attenuated vaccine for preventing F. tularensis, has secured US$14 million in awards from the USAFA. Under the USAFA Cooperative Agreement, Appili will manage a comprehensive development program, including nonclinical studies, CMC/manufacturing, clinical preparatory, and regulatory activities supporting an IND submission in 2025.

Appili has engaged with the U.S. Food and Drug Administration (“FDA”) via a pre-IND meeting, confirming the development pathway for ATI-1701, and is incorporating suggested changes into the development plan.

 

ATI-1801, Topical Antiparasitic Product in Advanced Clinical Development

ATI-1801, a novel topical formulation of paromomycin (15% w/w), is under advanced clinical development for treating cutaneous leishmaniasis, a disfiguring skin infection affecting hundreds of thousands globally.

Appili is currently engaging with the FDA, having submitted a type-B meeting request in 2024 to discuss linking previously generated Phase 3 data and agreeing on the necessary registration package for a New Drug Application submission. Appili aims to pursue non-dilutive funding and partnerships with NGOs and government agencies focused on tropical diseases to complete remaining development work.

ATI-1801 has received Orphan Drug Designation from the FDA for certain forms of cutaneous leishmaniasis. The company is evaluating ATI-1801’s eligibility for a priority review voucher (PRV), which, if confirmed, would make it the second PRV-eligible program at Appili, alongside ATI-1701, which is potentially eligible for a PRV pending renewal of certain U.S. legislation.

 

LIKMEZ™ (ATI-1501), FDA Approved Liquid Oral Reformulation of the Antibiotic Metronidazole

In September 2023, Appili, together with its U.S. partner, Saptalis Pharmaceuticals LLC., announced the approval by the United States Food and Drug Administration (“FDA”) of LIKMEZ™ (ATI-1501), a proprietary taste-masked liquid suspension formulation of metronidazole. LIKMEZ is the first FDA-approved ready-made suspension of metronidazole, addressing the unmet need in both pediatric patients and patients with dysphagia and mitigating risks associated with drug compounding and antimicrobial resistance.

LIKMEZ, with patent coverage through 2039, is the first and only FDA approved ready-made suspension of metronidazole for the treatment of antimicrobial infections that addresses the unmet need in patients with dysphagia to avoid risks associated with drug compounding, and discontinuation related anti-microbial resistance. Saptalis launched LIKMEZ in November 2023 and the product is now available to patients and doctors in the United States. Appili has the right to receive sales-based milestone payments and royalties from Saptalis based on sale of the product.

 

Aditxt Arrangement

On April 2, 2024, the Company announced that it had entered into a definitive arrangement agreement (the “Arrangement Agreement“) pursuant to which Aditxt Inc. (“Aditxt”), through its wholly-owned subsidiary, Adivir, Inc., agreed to acquire all of the issued and outstanding Class A common shares of the Company (“Common Shares”) by way of a court-approved plan of arrangement (the “Arrangement”) under the Canada Business Corporations Act. Under the terms of the Arrangement Agreement, shareholders of the Company will receive (i) 0.002745004 of a share of common stock of Aditxt and (ii) US$0.0467 in cash, for each Common Share held at the time of the closing of the proposed Arrangement. For further details regarding the Arrangement, please see Appili’s press release dated April 2, 2024 (the “Arrangement Press Release”).

Additional details of the Transaction will be described in the management information circular that will be mailed to the Appili Shareholders (the “Appili Circular”) in connection with a special meeting of the Appili Shareholders (the “Appili Meeting”) currently expected to be held in the fall of 2024 to approve the Transaction. Additional information regarding the terms of the Arrangement Agreement, the background to the Transaction, the rationale for the recommendations made by the Appili board of directors (on the basis of the recommendation of its independent special committee) and how shareholders can participate in and vote at the Appili Meeting will be provided in the Appili Circular.

 

Financial Results

The Company prepares its financial statements in accordance with IFRS Accounting Standards as issued by the International Accounting Standard Board and Part I of Chartered Professional Accountants of Canada Handbook–Accounting. All figures are stated in Canadian dollars unless otherwise stated.

The net loss and comprehensive loss of $1.6 million or $0.01 loss per share for the three months ended June 30, 2024, was $0.1 million higher than the net loss and comprehensive loss of $1.5 million or $0.01 loss per share during the three months ended June 30, 2023. This relates mainly to an increase in research and development expenses of $0.8 million, an increase in financing costs of $0.8 million and an increase of $0.2 million in foreign exchange loss. These increases were offset by an increase in government assistance of $1.6 million, and a decrease in general and administrative expenses by $0.1 million.

As of June 30, 2024, the Company had cash of $0.3 million, compared to $.1 million on March 31, 2024.

As of August 13, 2024, the Company had 121,266,120 issued and outstanding Common Shares, 11,520,281 stock options, and 41,356,874 warrants outstanding.

This press release should be read in conjunction with the Company’s unaudited interim condensed consolidated financial statements for the first quarter of the 2025 fiscal year and the related MD&A, copies of which are available under the Company’s profile on SEDAR+ at www.sedarplus.ca.

 

+++

 

About Appili Therapeutics

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infective s, including an FDA approved ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.

 

Forward looking statements

This news release contains “forward-looking statements”, including with respect to the funding commitment from USAFA and expected timing of invoice payment, advancing program towards IND, further anticipated milestones and the timing thereof, the Company’s development plans and timelines with respect to ATI-1501, ATI-1701 and ATI-1801, the timing of any milestone and/or royalty payments in respect of ATI-1501,  consideration to be received by shareholders in connection with the proposed Arrangement, the expected timing and process to complete the Arrangement, and the Company’s expectations with respect to its ability to operate as a going concern and satisfy its ongoing working capital requirements. Wherever possible, words such as “may,” “would,” “could,” “should,” “will,” “anticipate,” “believe,” “plan,” “expect,” “intend,” “estimate,” “potential for” and similar expressions have been used to identify these forward-looking statements. These forward-looking statements reflect the current expectations of the Company’s management for future growth, results of operations, performance and business prospects and opportunities and involve significant known and unknown risks, uncertainties and assumptions, including, without limitation, those listed in the annual information form of the Company dated June 25, 2024, and the other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedarplus.ca). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.

All statements included in this press release relating to the Arrangement are qualified by reference to the “Forward Looking Statements” section included in the Arrangement Press Release.

 

###

 

Media Contact:

Jenna McNeil, Communications Manager

Appili Therapeutics

E: [email protected]

 

Investor Relations Contact:

Don Cilla, President and CEO

Appili Therapeutics

E: [email protected]